Communiqués Enlivex

Actions

ENLV

IL0011319527

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/07/2026			Varia. 5j.	Varia. 1 janv.
4,200 ^USD	-3,67%		-10,26%	-60,18%

13/07	Enlivex reçoit la désignation RMAT de la FDA pour Allocetra dans le traitement de l'arthrose du genou liée à l'âge	CI
15/06	Enlivex Therapeutics obtient un brevet en Australie pour l'Allocetra dans le traitement de l'arthrose	MT

Communiqués

20/07	Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion	GL
13/07	Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis	GL
13/07	Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis	AQ
07/07	Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026	GL
07/07	Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026	AQ
24/06	Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume	GL
24/06	Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume	AQ
22/06	Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion	GL
15/06	Enlivex : Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis	PU
15/06	Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis	GL
02/06	Enlivex Ltd. - Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial, Oral Presentation at EULAR 2026	AQ
02/06	ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026	GL
02/06	ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026	AQ
01/06	Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026	GL
01/06	Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026	AQ
28/05	Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board	GL
28/05	Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board	AQ
27/05	Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity	GL
27/05	Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity	AQ
18/05	Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification	AQ
18/05	Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis	GL
18/05	Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis	AQ
15/05	Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification	GL
30/04	Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange	GL
28/04	Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million	GL